Could you give 15 minutes of your time and a blood sample to help our research?

Are you based in Leeds?

We are a melanoma research group led by Professor JA Newton-Bishop and we aim to develop a blood test that measures immune function.

We are doing this by comparing the genetic information in the immune cells of individuals who have illnesses that affect the immune system such as cancer and inflammatory disease.

Crucially, we need to establish what is ‘normal’ genetic information in immune cells and we will do this by looking at the blood of healthy people.

We need volunteers to donate 21ml of blood, answer a short health questionnaire and have basic measurements taken such as height, weight and blood pressure.
You could help us if you are:
·         Aged 18-66 (70 if have previously given blood)


Unfortunately we are unable to recruit people to this study who:
·         Have suffered with cancer in the last 5 years
·         Have an auto-immune disease (such as Rheumatoid arthritis, lupus, psoriasis)
·         Have diabetes
·         Have significant cardiovascular disease
·         Have any infectious illness such as TB, Hepatitis or HIV


See our website for further information and to book an appointment with a researcher to take part:

We are currently recruiting from St James’s hospital. If you are based at LGI or the University and are keen to volunteer please contact our researchers via the website and we can arrange to come and see you closer to your work place.

Thank you in advance for your help,

Yours faithfully,

Dr Sarah Craig
Academic Clinical Fellow

Christy Walker
Senior Research Nurse

On behalf of:
Professor Julia Newton-Bishop
Professor of Dermatology
Section of Epidemiology and Biostatistics

Option Grids: information for melanoma patients

NICE has worked with Option Grid and UK dermatologists Jason Thomson and Jane McGregor, to produce information for melanoma patients and their medical teams. The information is provided in the form of Option Grids which allow consideration of the potential advantages and disadvantages of given medical procedures or treatments. The new grids relate to sentinel node biopsy and whether or not to have regular CT (body) scans after their melanoma diagnosis.

Option Grid Sentinel Node Biopsy yes or no

Option Grid Completion Lymphadenectomy yes or no

Option Grid. Follow up with regular CT scans Yes or No

BAP1: a newly recognised melanoma gene

GenoMEL has some new information in the Information for Patients section, on a rare inherited genetic mutation which increases the risk of melanoma in some families. The appearance of the moles and the melanomas in these families can be unusual and affected families are also at increased risk of other cancers such as mesothelioma and eye (uveal) melanoma.

NICE Clinical Melanoma Guideline

NICE published the Clinical Melanoma Guideline in July 2015. This Guideline is directed at secondary and tertiary care (hospital treatment) in the UK and considers the role of treatments such as sentinel node biopsy.

This is a link to the guideline

The Guideline addressed the role of sentinel node biopsy and regular body scans after diagnosis, among other  issues. The decision was made to develop information for melanoma patients about the advantages and disadvantages of sentinel node biopsy and regular imaging. This information was developed in conjunction with Option Grid and was published in December 2015. The grids can be obtained direct from the Option Grid web page but are also provided in the Option Grid post.



Vitamin D and melanoma: new podcast

NICE asked Professor Julia Newton-Bishop to discuss why vitamin D was considered by the Clinical Melanoma Guideline and this is the link to her podcast